{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:04:20Z","timestamp":1791475460191,"version":"4.3.4"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,26]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Anaemia is one of the most common complications of chronic kidney disease (CKD), having a significant impact on quality of life, and is also associated with a number of adverse clinical outcomes. Its pathogenesis is multifactorial, caused largely by an inadequate production of erythropoietin from the diseased kidneys, with iron deficiency, inflammation, shortened red cell lifespan and enhanced blood loss also being contributory factors. The management of this condition was transformed in the late 1980s by the advent of recombinant human erythropoietin (epoetin), and treatment paradigms have developed over the last three decades, largely focusing on a combination of epoetin or its analogues (erythropoiesis-stimulating agents; ESAs) along with iron supplementation, often administered intravenously due to increased hepcidin levels limiting iron absorption from the gut. Indeed, in patients with early CKD and iron deficiency, iron per se may be sufficient to improve the anaemia, delaying the need for ESA therapy. Other causes of anaemia should be excluded and corrected (if possible) before resorting to treatment with ESAs and iron. More recently, the hypoxia-inducible factor\u2013prolyl hydroxylase inhibitors have entered the therapeutic arena; these are orally active agents that upregulate endogenous erythropoietin production as well as a number of iron-regulatory genes which may also enhance erythropoiesis. The latter drugs are highly efficacious, and may have advantages in inflammatory conditions causing resistance to conventional ESA therapy, but concerns exist regarding their safety, particularly in the longer term. This article reviews the current standards of treatment, as well as recent novel developments in the management of anaemia in CKD.<\/jats:p>","DOI":"10.1093\/ndt\/gfad250","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T03:59:11Z","timestamp":1701143951000},"page":"770-777","source":"Crossref","is-referenced-by-count":55,"title":["Anaemia in CKD\u2014treatment standard"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9804-0657","authenticated-orcid":false,"given":"Iain C","family":"Macdougall","sequence":"first","affiliation":[{"name":"Department of Renal Medicine, King's College Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"2024042523511838800_bib1","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/archinte.162.12.1401","article-title":"Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994)","volume":"162","author":"Astor","year":"2002","journal-title":"Arch Intern Med"},{"key":"2024042523511838800_bib2","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1172\/JCI114280","article-title":"Erythropoietin in polycystic kidneys","volume":"84","author":"Eckardt","year":"1989","journal-title":"J Clin Invest"},{"key":"2024042523511838800_bib3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/pdi.885","article-title":"Anaemia in diabetic kidney disease: an area for improvement?","volume":"23","author":"Thomas","year":"2006","journal-title":"Practical Diabetes Int"},{"key":"2024042523511838800_bib4","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"KDIGO Anemia Guideline Work Group","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2024042523511838800_bib5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/16.1.111","article-title":"Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients","volume":"16","author":"Movilli","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"2024042523511838800_bib6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1054\/mehy.1999.0027","article-title":"Pathogenesis of anaemia in hyperparathyroidism","volume":"54","author":"Sikole","year":"2000","journal-title":"Med Hypotheses"},{"key":"2024042523511838800_bib7","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1681\/ASN.2019020213","article-title":"Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment","volume":"31","author":"Batchelor","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2024042523511838800_bib8","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/ndt\/16.7.1416","article-title":"The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin","volume":"16","author":"Tessitore","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"2024042523511838800_bib9","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2024042523511838800_bib10","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"},{"key":"2024042523511838800_bib11","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1046\/j.1523-1755.1999.055Suppl.69061.x","article-title":"Strategies for iron supplementation: oral versus intravenous","volume":"55","author":"Macdougall","year":"1999","journal-title":"Kidney Int"},{"key":"2024042523511838800_bib12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.semnephrol.2016.02.001","article-title":"Iron balance and the role of hepcidin in chronic kidney disease","volume":"36","author":"Ganz","year":"2016","journal-title":"Semin Nephrol"},{"key":"2024042523511838800_bib13","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.V10112392","article-title":"Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients","volume":"10","author":"Macdougall","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"2024042523511838800_bib14","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2215\/CJN.00730306","article-title":"Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease","volume":"1","author":"Macdougall","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024042523511838800_bib15","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"2024042523511838800_bib16","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N Engl J Med"},{"key":"2024042523511838800_bib17","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"2024042523511838800_bib18","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"2024042523511838800_bib19","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3390\/microbiolres12020033","article-title":"Oral iron supplementation - gastrointestinal side-effects and the impact on the gut microbiota","volume":"12","author":"Bloor","year":"2021","journal-title":"Microbiol Res"},{"issue":"Suppl","key":"2024042523511838800_bib20","first-page":"1","article-title":"European Best Practice guidelines for the management of anaemia in patients with chronic kidney failure","volume":"14","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"2024042523511838800_bib21","first-page":"5447","article-title":"A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation","volume":"12","author":"Semenza","year":"1992","journal-title":"Mol Cell Biol"},{"key":"2024042523511838800_bib22","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1126\/science.1066373","article-title":"A conserved family of prolyl-4-hydroxylases that modify HIF","volume":"294","author":"Bruick","year":"2001","journal-title":"Science"},{"key":"2024042523511838800_bib23","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2024042523511838800_bib24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD","volume":"69","author":"Gupta","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2024042523511838800_bib25","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1681\/ASN.2010010116","article-title":"Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD","volume":"21","author":"Bernhardt","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2024042523511838800_bib26","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2024042523511838800_bib27","first-page":"598","article-title":"Regulation of iron metabolism by hypoxia-inducible factors","volume":"69","author":"Xu","year":"2017","journal-title":"Sheng Li Xue Bao"},{"key":"2024042523511838800_bib28","doi-asserted-by":"crossref","first-page":"100102","DOI":"10.1016\/j.crphar.2022.100102","article-title":"Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state","volume":"3","author":"Joharapurkar","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"2024042523511838800_bib29","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"2024042523511838800_bib30","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"2024042523511838800_bib31","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and nondialysis-dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N Engl J Med"},{"key":"2024042523511838800_bib32","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and efficacy of vadadustat for anemia in patients undergoing dialysis","volume":"384","author":"Eckardt","year":"2021","journal-title":"N Engl J Med"},{"key":"2024042523511838800_bib33","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"2024042523511838800_bib34","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the treatment of anemia in patients undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"2024042523511838800_bib35","article-title":"FibroGen announces positive phase 3 pooled roxadustat safety and efficacy results for treatment of anemia","author":"FibroGen Press Release"},{"key":"2024042523511838800_bib36","article-title":"FibroGen receives Complete Response Letter from the FDA for roxadustat for anemia of chronic kidney disease","author":"FibroGen Press Release"},{"key":"2024042523511838800_bib37","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1159\/000518071","article-title":"Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial","volume":"52","author":"Yamamoto","year":"2021","journal-title":"Am J Nephrol"},{"key":"2024042523511838800_bib38","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.ekir.2021.04.037","article-title":"A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study","volume":"6","author":"Akizawa","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2024042523511838800_bib39","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000523961","article-title":"Desidustat in anemia due to non-dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-ND)","volume":"53","author":"Agrawal","year":"2022","journal-title":"Am J Nephrol"},{"key":"2024042523511838800_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10409238.2013.838205","article-title":"Transcriptional regulation by hypoxia inducible factors","volume":"49","author":"Dengler","year":"2014","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"2024042523511838800_bib41","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ki.2014.275","article-title":"Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality","volume":"87","author":"Bailie","year":"2015","journal-title":"Kidney Int"},{"key":"2024042523511838800_bib42","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1681\/ASN.2005040423","article-title":"Time-dependent associations between iron and mortality in hemodialysis patients","volume":"16","author":"Kalantar-Zadeh","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2024042523511838800_bib43","doi-asserted-by":"crossref","first-page":"130172","DOI":"10.1016\/j.bbagen.2022.130172","article-title":"Iron overload, oxidative stress and vascular dysfunction: evidences from clinical studies and animal models","volume":"1866","author":"Dos Santos","year":"2022","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"2024042523511838800_bib44","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/ckj\/sfv142","article-title":"Safety concerns about intravenous iron therapy in patients with chronic kidney disease","volume":"9","author":"Del Vecchio","year":"2016","journal-title":"Clin Kidney J"},{"key":"2024042523511838800_bib45","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1523-1755.2003.00125.x","article-title":"High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity","volume":"64","author":"Deicher","year":"2003","journal-title":"Kidney Int"},{"key":"2024042523511838800_bib46","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1681\/ASN.2019090972","article-title":"Intravenous iron dosing and infection risk in patients on hemodialysis: a prespecified secondary analysis of the PIVOTAL Trial","volume":"31","author":"Macdougall","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2024042523511838800_bib47","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1016\/j.ekir.2021.07.032","article-title":"Iron deficiency in CKD without concomitant anemia","volume":"6","author":"Wish","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2024042523511838800_bib48","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","article-title":"Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference","volume":"99","author":"Babitt","year":"2021","journal-title":"Kidney Int"},{"key":"2024042523511838800_bib49","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.kint.2023.05.009","article-title":"Novel anemia therapies in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"104","author":"Ku","year":"2023","journal-title":"Kidney Int"},{"key":"2024042523511838800_bib50","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1053\/j.ajkd.2021.06.019","article-title":"Hypoxia-inducible factor stabilization as an emerging therapy for CKD-related anemia: report from a scientific workshop sponsored by the National Kidney Foundation","volume":"78","author":"Wish","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2024042523511838800_bib51","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfae075","article-title":"Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitors for the treatment of anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)","author":"Stoumpos","year":"2024","journal-title":"Nephrol Dial Transplant"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfad250\/56757098\/gfad250.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/5\/770\/57332498\/gfad250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/5\/770\/57332498\/gfad250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T23:52:15Z","timestamp":1714089135000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/39\/5\/770\/7452913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":51,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,11,27]]},"published-print":{"date-parts":[[2024,4,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfad250","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2023,11,27]]}}}